Biphenyl Dimethyl Dicarboxylate
drugOn this page
Also known as Dimethyl 4,4'-biphenyldicarboxylateNisseldimethyl biphenyl-4,4'-dicarboxylate
Summary
Biphenyl Dimethyl Dicarboxylate (CHEMBL4297409) is a phase-3 clinical-stage small molecule; indicated across 1 condition including liver disorder.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 1 condition
- Clinical trials: 1
- Chemistry: 270.28 Da · C16H14O4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297409 |
| Name | Biphenyl Dimethyl Dicarboxylate |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 13099 |
| Molecular formula | C16H14O4 |
| Molecular weight | 270.28 |
| InChIKey | BKRIRZXWWALTPU-UHFFFAOYSA-N |
SMILES: COC(=O)C1=CC=C(C=C1)C2=CC=C(C=C2)C(=O)OC
IUPAC name: methyl 4-(4-methoxycarbonylphenyl)benzoate
Also known as: Biphenyl dimethyl dicarboxylate, Dimethyl 4,4’-biphenyldicarboxylate, Nissel, BIPHENYL DIMETHYL DICARBOXYLATE, dimethyl biphenyl-4,4’-dicarboxylate
Patent coverage: 216 distinct patent families (483 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| liver disorder | 3 | MONDO:0005154 | EFO:0001421 |
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01393678 | PHASE3 | COMPLETED | Study to Evaluate Efficacy and Safety of PENNEL Capsule in the Patients With Chronic Liver Disease |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: liver disorder